EA201071300A1 - ANTIBODIES TO CXCR4 - Google Patents

ANTIBODIES TO CXCR4

Info

Publication number
EA201071300A1
EA201071300A1 EA201071300A EA201071300A EA201071300A1 EA 201071300 A1 EA201071300 A1 EA 201071300A1 EA 201071300 A EA201071300 A EA 201071300A EA 201071300 A EA201071300 A EA 201071300A EA 201071300 A1 EA201071300 A1 EA 201071300A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
cxcr4
present
metastasis
angiogenesis
Prior art date
Application number
EA201071300A
Other languages
Russian (ru)
Inventor
Синди Такеучи Дикерсон
Дэвид Мэттью Маркис
Виктор Обунгу
Шэн-бинь Пэн
Питер Эдвард Вайлланкур
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201071300A1 publication Critical patent/EA201071300A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Настоящее изобретение обеспечивает антитела, которые связывают CXCR4 человека и известны в данной области техники как обладающие высоким сродством и сильными нейтрализующими свойствами. Антитела согласно настоящему изобретению применяют для лечения опухолеобразования, включая рост опухоли, инвазию, ангиогенез или метастазирование.The present invention provides antibodies that bind human CXCR4 and are known in the art as having high affinity and strong neutralizing properties. Antibodies of the present invention are used to treat tumor formation, including tumor growth, invasion, angiogenesis or metastasis.

EA201071300A 2008-05-14 2009-05-07 ANTIBODIES TO CXCR4 EA201071300A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US5319208P 2008-05-14 2008-05-14
PCT/US2009/043063 WO2009140124A1 (en) 2008-05-14 2009-05-07 Anti-cxcr4 antibodies

Publications (1)

Publication Number Publication Date
EA201071300A1 true EA201071300A1 (en) 2011-06-30

Family

ID=40852496

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071300A EA201071300A1 (en) 2008-05-14 2009-05-07 ANTIBODIES TO CXCR4

Country Status (11)

Country Link
EP (1) EP2297206A1 (en)
JP (1) JP2011520885A (en)
KR (1) KR20100133012A (en)
CN (1) CN102027015A (en)
AU (1) AU2009246683A1 (en)
CA (1) CA2724409A1 (en)
EA (1) EA201071300A1 (en)
IL (1) IL208869A0 (en)
MX (1) MX2010012435A (en)
WO (1) WO2009140124A1 (en)
ZA (1) ZA201007955B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2172485A1 (en) * 2008-10-01 2010-04-07 Pierre Fabre Medicament Novel anti CXCR4 antibodies and their use for the treatment of cancer
US9155780B2 (en) 2009-02-11 2015-10-13 Yeda Research And Development Co. Ltd. Short beta-defensin-derived peptides
EP2246364A1 (en) * 2009-04-29 2010-11-03 Pierre Fabre Médicament Anti CXCR4 antibodies for the treatment of HIV
GB201002238D0 (en) 2010-02-10 2010-03-31 Affitech As Antibodies
EP2371863A1 (en) * 2010-03-30 2011-10-05 Pierre Fabre Médicament Humanized anti CXCR4 antibodies for the treatment of cancer
JP2014504147A (en) * 2010-10-27 2014-02-20 ピエール、ファーブル、メディカマン HIV therapeutic antibody
US20140120555A1 (en) * 2011-06-20 2014-05-01 Pierre Fabre Medicament Anti-cxcr4 antibody with effector functions and its use for the treatment of cancer
WO2012178137A1 (en) 2011-06-24 2012-12-27 Gillies Stephen D Light chain immunoglobulin fusion proteins and methods of use thereof
JP2014523745A (en) * 2011-07-20 2014-09-18 メディミューン リミテッド Anti-CXCR4 antibody and method of use
AR087364A1 (en) 2011-07-29 2014-03-19 Pf Medicament ANTI-CXCR4 ANTIBODY AND ITS USE FOR CANCERES DETECTION AND DIANOSTIC
RS58102B1 (en) * 2011-11-09 2019-02-28 Bristol Myers Squibb Co Treatment of hematologic malignancies with an anti-cxcr4 antibody
TWI612059B (en) * 2013-03-15 2018-01-21 美國禮來大藥廠 Pan-elr+ cxc chemokine antibodies
CA2989144A1 (en) 2015-06-12 2016-12-15 Bristol-Myers Squibb Company Treatment of cancer by combined blockade of the pd-1 and cxcr4 signaling pathways
KR102531889B1 (en) 2016-06-20 2023-05-17 키맵 리미티드 Anti-PD-L1 and IL-2 cytokines
EP3765519B1 (en) 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
EP3973274A1 (en) 2019-05-23 2022-03-30 Bristol-Myers Squibb Company Methods of monitoring cell culture media
JP2023544410A (en) 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー Methods for concentrating proteins
CN112521500B (en) * 2020-12-25 2022-06-24 暨南大学 Affinity maturation binding proteins that bind to CXCR4 and uses thereof
CN112661845B (en) * 2020-12-25 2022-06-21 暨南大学 Affinity maturation binding protein bound with CXCR4 and application thereof
WO2023173011A1 (en) 2022-03-09 2023-09-14 Bristol-Myers Squibb Company Transient expression of therapeutic proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19801265C1 (en) * 1998-01-15 1999-08-12 Deutsches Krebsforsch Inhibition of CD95-independent apoptosis in AIDS
US20050002939A1 (en) * 2002-12-23 2005-01-06 Albert Zlotnik Tumor killing/tumor regression using CXCR4 antagonists
EP1871807B1 (en) * 2005-02-18 2012-11-28 Dana-Farber Cancer Institute, Inc. Antibodies against cxcr4 and methods of use thereof
EP2486941B1 (en) * 2006-10-02 2017-03-15 E. R. Squibb & Sons, L.L.C. Human antibodies that bind CXCR4 and uses thereof
FR2915102B1 (en) * 2007-04-23 2014-05-16 Pf Medicament USE OF ANTI-CXCR4 ANTIBODY FOR THE TREATMENT OF CANCER

Also Published As

Publication number Publication date
CN102027015A (en) 2011-04-20
AU2009246683A1 (en) 2009-11-19
EP2297206A1 (en) 2011-03-23
CA2724409A1 (en) 2009-11-19
WO2009140124A1 (en) 2009-11-19
MX2010012435A (en) 2011-05-03
IL208869A0 (en) 2011-01-31
JP2011520885A (en) 2011-07-21
ZA201007955B (en) 2012-04-25
KR20100133012A (en) 2010-12-20

Similar Documents

Publication Publication Date Title
EA201071300A1 (en) ANTIBODIES TO CXCR4
EA200970874A1 (en) ANTIBODIES AGAINST SKLEROSTIN
EA201590085A1 (en) ANTIBODIES ANTI-EGFR AND THEIR APPLICATION
EA201490717A1 (en) ANTIBODIES TO ErbB3 AND THEIR APPLICATION
EA201390472A1 (en) NEW MOLECULES CONNECTING WITH EGFR AND THEIR IMMUNOCONJUGATES
EA201201000A1 (en) METHODS OF TREATMENT OF COLORECTAL CANCER
MX2018015915A (en) Specific binding proteins and uses thereof.
EA201170155A1 (en) SPECIFIC ANTAGONISTS OF FGF-R4 RECEPTOR
NZ599737A (en) Il-17a antagonists
MY177062A (en) Cd37-binding molecules and immunoconjugates thereof
UA112416C2 (en) FAP ANTIBODY AND METHODS OF ITS APPLICATION
EA201200473A1 (en) SUBSTITUTED (HETEROARILMETHYL) THIOGIDANTOINES
MX348637B (en) Anti-her3 antibodies and compositions.
JO3097B1 (en) c-Met Antibodies
EA201001639A1 (en) COMPOSITIONS AND METHODS FOR THEIR PRODUCTION AND APPLICATION
MX2012001262A (en) Dual variable domain immunoglobulins and uses thereof.
MX2011011669A (en) Dual variable domain immunoglobulins and uses thereof.
MY163368A (en) Il-1-alpha and -beta bispecific dual variable domain immunoglobulins and their use
TN2011000528A1 (en) Compositions and methods for antibodies targeting complement protein c3b
EA201170288A1 (en) OXABICYCLOPTANES AND OXABICYCLOPTENS
MX2010003013A (en) Inhibition of angiogenesis.
EA201171237A1 (en) ANTIBODIES TO DKK-1
EA201290360A1 (en) HUMANIZED ANTIBODIES AGAINST HUMAN IL-22RA
EA201691384A2 (en) CONSTRUCTIONS OF THE SIRP-ALPHA OPTION AND THEIR APPLICATION
MX2012001306A (en) Inhibition of tumor metastasis using bv8- or g-csf-antagonists.